Lantheus Holdings Inc. (NASDAQ:LNTH)’s share price shot up 4.8% during mid-day trading on Thursday . The company traded as high as $7.75 and last traded at $7.44, with a volume of 279,427 shares trading hands. The stock had previously closed at $7.10.

A number of research firms have issued reports on LNTH. Zacks Investment Research upgraded Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $7.00 price target for the company in a research note on Monday, August 8th. Credit Suisse Group AG set a $4.00 target price on shares of Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday, August 5th. Finally, Jefferies Group reissued a “buy” rating on shares of Lantheus Holdings in a research report on Wednesday, May 4th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Lantheus Holdings has a consensus rating of “Buy” and an average target price of $5.80.

The company has a 50-day moving average of $5.06 and a 200-day moving average of $2.91. The stock has a market cap of $239.75 million and a PE ratio of 8.91.

Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.18. The company earned $78 million during the quarter, compared to the consensus estimate of $72.66 million. Equities analysts forecast that Lantheus Holdings Inc. will post $0.53 earnings per share for the current year.

Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.